eXoZymes (NASDAQ:EXOZ – Get Free Report) and Upstream Bio (NASDAQ:UPB – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.
Valuation and Earnings
This table compares eXoZymes and Upstream Bio”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| eXoZymes | $70,000.00 | 391.09 | -$9.16 million | ($1.16) | -2.50 |
| Upstream Bio | $2.85 million | 30.58 | -$143.44 million | ($3.02) | -0.53 |
eXoZymes has higher earnings, but lower revenue than Upstream Bio. eXoZymes is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
eXoZymes has a beta of 3.34, indicating that its stock price is 234% more volatile than the S&P 500. Comparatively, Upstream Bio has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for eXoZymes and Upstream Bio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| eXoZymes | 1 | 1 | 0 | 0 | 1.50 |
| Upstream Bio | 1 | 2 | 4 | 0 | 2.43 |
Upstream Bio has a consensus price target of $26.67, suggesting a potential upside of 1,577.15%. Given Upstream Bio’s stronger consensus rating and higher probable upside, analysts plainly believe Upstream Bio is more favorable than eXoZymes.
Profitability
This table compares eXoZymes and Upstream Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| eXoZymes | N/A | -376.71% | -170.21% |
| Upstream Bio | -5,712.33% | -57.09% | -54.69% |
Summary
Upstream Bio beats eXoZymes on 6 of the 11 factors compared between the two stocks.
About eXoZymes
eXoZymes is a biotechnology company focused on cell-free biomanufacturing. Its approach uses enzymes outside living cells to produce compounds, offering an alternative to conventional manufacturing methods. The company’s work centers on developing its biomanufacturing platform and applying it to the production of useful molecules. Publicly available information about specific commercial products, customer markets, geographic reach and company leadership is limited.
About Upstream Bio
Upstream Bio is a clinical-stage biopharmaceutical company developing treatments for inflammatory diseases. The company is based in Waltham, Massachusetts, and its research focuses on pathways involved in immune and inflammatory responses. Its lead product candidate, verekitug (UPB-101), is an antibody designed to block the receptor for thymic stromal lymphopoietin, a protein associated with inflammation. Upstream Bio is developing verekitug for conditions including asthma and chronic rhinosinusitis with nasal polyps.
Receive News & Ratings for eXoZymes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for eXoZymes and related companies with MarketBeat.com's FREE daily email newsletter.
